1. Scrip
  2. >>Focus On Asia

India Corporate Governance Practices – Will Pharma Walk The Gandhian Path?

 
• By Anju Ghangurde

As Sun Pharma firefights allegations of corporate governance lapses, Scrip speaks to multiple experts on how they view the governance landscape across Pharma Inc in India and also some key sticking points.

SC1812_Gandhi_ 272755796_1200.jpg
CORPORATE GOVERNANCE PRACTICES ARE IN THE SPOTLIGHT IN INDIA

An expert panel on corporate governance, in a report last year, broadly put the styles of running companies across sectors in India into two buckets - the “Raja” (Monarch) model and the “Custodian” (Trusteeship) model.

Self-interest precedes interests of other stakeholders in the former, while the latter essentially works on “Gandhian Principles” – where the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 
• By Anju Ghangurde

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.